New cocktail of four drugs takes on Hard-to-Treat myeloma
NCT ID NCT07150104
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study is testing a combination of four drugs (belantamab mafodotin, nirogacestat, pomalidomide, and dexamethasone) in 14 people with multiple myeloma that has returned or stopped responding to at least three prior treatments. The main goals are to check safety and find the right dose. Researchers will also look at whether the treatment shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
belantamab mafodotin, nirogacestat, pomalidomide, and dexamethasone
What this could lead to
If this combination works, it could offer a new treatment option for people with multiple myeloma that has stopped responding to other therapies.
What could go wrong
This is a very early, small study (14 people) focused on safety and dosing. The combination may cause serious side effects, and it is too soon to know if it will be effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Salvador, Estado de Bahia, 41253-190, Brazil
-
GSK Investigational Site
Porto Alegre, Rio Grande do Sul, 90110-270, Brazil
-
GSK Investigational Site
Halifax, Nova Scotia, B3H 1V7, Canada
-
GSK Investigational Site
Villejuif, 94805, France
-
GSK Investigational Site
Mexico City, 01330, Mexico
-
GSK Investigational Site
Oslo, 0450, Norway
-
GSK Investigational Site
Lublin, 20-081, Poland
-
GSK Investigational Site
Seoul, 03080, South Korea
-
GSK Investigational Site
Ulsan, 44033, South Korea
-
GSK Investigational Site
Falun, SE-791 82, Sweden